Schiff Andrew N's Form 4 filing
Aclaris Therapeutics, Inc. (ACRS) · filed Nov 14, 2022
- Accession no.
- 0001209191-22-056644
- Filed
- Nov 14, 2022
- Trade date
- Nov 10-14, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $919.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schiff Andrew NCIK 0001172252 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 10, 2022 | Common Stock | SSaleDisposed | −11,395 | $17.02 | −$193,942.9 | 476,986 | Indirect | |
| Nov 11, 2022 | Common Stock | SSaleDisposed | −41,160 | $17.06 | −$702,189.6 | 435,826 | Indirect | |
| Nov 14, 2022 | Common Stock | SSaleDisposed | −1,371 | $17.08 | −$23,416.68 | 434,455 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.